home > news > detailed info

Quanticate Announces Plans to Accelerate Growth in North America


Hitchin, UK, 8TH NOVEMBER – Quanticate, a global data-focused clinical research organisation (CRO), has announced plans for further expansion and new jobs in 2023 as it thrives post-pandemic.

The UK-headquartered firm opened its Toronto office in 2019 to facilitate the increasing customer base in the North American market. Since opening, it has seen its team double in size in the last year.

Now the firm is expanding further with plans for a number of additional jobs in the next year across the business.

“Our North American team of highly qualified statisticians and programmers have worked exceptionally hard and delivered excellent results. Market demand for our services skyrocketed post-pandemic which led us to commit to strengthening our North American team to ensure we continued to deliver our exceptional operations, stats and programming services to our existing and new customers” commented David Underwood, CEO of Quanticate.

Underwood continued: “Our team expansion in Canada meets the growing demand from clients in the North American market to help form effective and efficient partnerships.”

“I’m delighted that our world-class services attract some of the best talent in the industry and I look forward to continuing to successfully deliver high-quality data-focused services.”

Quanticate is one of the world’s largest global data-focused clinical research organizations (CROs) with a primary focus on data capture, statistical analysis, and clinical trial reporting. Find out more about the business and its service offerings here.
phone +44 (0)1462 440 084
email Bevan House, 9-11 Bancroft Court Hitchin, Hertfordshire, SG5 1LH
Print this page
Send to a friend
News and Press Releases

Ascelia Pharma meets major milestone with patient enrollment completion of Phase 3 Study for Orviglance, novel MRI contrast agent for patients with kidney impairment

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of patient enrollment in the company’s pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance®.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement